Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Pfizer (PFE) heads into its Morgan Stanley Global Healthcare Conference presentation on 14 September with investors watching ...

・PFE stock closed up 1.65% amid growing optimism for its vaccine pipelines. ・GTLB stock gained nearly 10% at close on Wednesday on strong fiscal second-quarter results and Wall Street price-target ...

Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

August 29, 2026I analyzed Pfizer once before in April. At that time, the stock price was $27.22, and looking at the figures—a ...

I last covered Pfizer Inc. stock (NYSE:PFE) on Feb 19. The article rated the stock as hold after examining its FQ4 earnings report (ER) and dividend declarations. Since then, a few new catalysts have ...

Pfizer just got a reality check from one of Wall Street’s biggest banks, and the timing could not be more awkward heading into the second half of the year. HSBC downgraded Pfizer to Hold from Buy on ...

PFE trades at a 9x forward P/E with a 6.58% dividend yield, supporting a $32.92 price target and 26% upside potential. Non-COVID revenue grew 9% operationally in Q4 2025, led by Abrysvo surging 136%, ...

Since November 2021, I've been bullish on Pfizer Inc.'s (PFE) stock, actively arguing that the LOEs they were supposed to go through weren't actually changing the long-term fundamental picture: The ...